Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cardiff Oncology, Inc.NASDAQ: CRDF

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q1 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was -2105.7%, down 548.4 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
-2105.7%-548.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How CRDF compares with its peers on the latest reported figures

  • CRDF's LTM Mar 2026 gross margin of -2105.7% is the lowest of the 4 companies compared; the peer median is 94.9%.
  • Its year-over-year change of -548.4 pp is the lowest of 3, against a peer median of -2.5 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +41.1 pp.
CRDF Competitors Peer median
Gross Margin for CRDF and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 202694.9% -5.1 pp—
MISTMilestone Pharmaceuticals Inc.LTM Mar 202694.7% —-7.4 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
FBRXForte Biosciences, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding CRDF) 94.9%-2.5 pp+41.1 pp

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue359K386K488K683K593K
Cost of Revenue00000
Gross Profit359K386K488K683K593K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development17.38M27.11M32.86M36.85M35.33M
Selling, General & Admin11.84M13.18M13.04M12.48M14.22M
Operating Expenses29.21M40.29M45.9M49.33M49.55M
Depreciation & Amortization451K236K398K404K904K
EBITDA(27.84M)(38.47M)(41.04M)(45.03M)(44.95M)
EBITDA Margin-7754.9%-9965.8%-8410.5%-6592.5%-7579.6%
Operating Income(28.86M)(39.9M)(45.41M)(48.65M)(48.96M)
Operating Margin-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
Interest Income264K1.58M4.07M3.26M3.1M
Interest Expense00000
Other Income / Expenses564K1.2M3.97M3.22M3.11M
Income Before Tax(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Pre-Tax Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
Income Tax Expense00000
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Net Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
EPS (Basic)(0.73)(0.89)(0.93)(0.95)(0.69)
EPS (Diluted)(0.73)(0.89)(0.93)(0.95)(0.69)
Weighted Avg Shares39.03M43.6M44.68M47.65M66.84M
Weighted Avg Shares (Diluted)39.03M43.6M44.68M47.65M66.84M

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.